ID: ALA2376321

Max Phase: Preclinical

Molecular Formula: C19H19F2N3O5S

Molecular Weight: 439.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC[C@]1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(OC(F)F)cc3)ccc2NC1=O

Standard InChI:  InChI=1S/C19H19F2N3O5S/c1-3-19(2)17(26)22-15-9-8-13(10-14(15)16(25)23-19)30(27,28)24-11-4-6-12(7-5-11)29-18(20)21/h4-10,18,24H,3H2,1-2H3,(H,22,26)(H,23,25)/t19-/m0/s1

Standard InChI Key:  QBHUGPKPNMGAOH-IBGZPJMESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 439.44

Molecular Weight (Monoisotopic): 439.1013

AlogP: 2.94

#Rotatable Bonds: 6

Polar Surface Area: 113.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.94

CX Basic pKa:

CX LogP: 3.42

CX LogD: 3.32

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.64

Np Likeness Score: -1.43

References

1. Barlind JG, Buckett LK, Crosby SG, Davidsson Ö, Emtenäs H, Ertan A, Jurva U, Lemurell M, Gutierrez PM, Nilsson K, O'Mahony G, Petersson AU, Redzic A, Wågberg F, Yuan ZQ..  (2013)  Identification and design of a novel series of MGAT2 inhibitors.,  23  (9): [PMID:23541669] [10.1016/j.bmcl.2013.02.084]

Source

Source(1):

• Scientific Literature